This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Looking for Dividend Growth? Here Are 5 Solid Picks
by Sweta Killa
Investors are once again in search for consistent and safe income in a near-zero interest environment, a series of drastic dividend cuts and rising U.S.-China tension.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to benefit from broad product portfolio and persistent focus on R&D. However, forex remains a woe.
Here's Why You Should Hold on to Nevro (NVRO) Stock Now
by Zacks Equity Research
Nevro (NVRO) is gaining traction from strengthening international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.
Baxter Receives CE Marking for Evo IQ Syringe Infusion System
by Zacks Equity Research
Baxter (BAX) receives the CE marking and regulatory approval for the Evo IQ Syringe Infusion system that will help in optimizing efficiency for clinicians.
Cerner and Hospital IQ Partner to Boost Clinical Awareness
by Zacks Equity Research
Cerner (CERN) partners with Hospital IQ to help health systems with predictive analytics to enhance clinical and operational awareness.
Veeva Systems Boosts Product Portfolio With New Application
by Zacks Equity Research
Veeva Systems (VEEV) announces a new application called MyVeeva to enable patient-centric clinical trials.
Zacks.com featured highlights include: NextEra Energy, Kinsale Capital Group, Vectrus, Teekay Tankers and West Pharmaceutical Services
by Zacks Equity Research
Zacks.com featured highlights include: NextEra Energy, Kinsale Capital Group, Vectrus, Teekay Tankers and West Pharmaceutical Services
OPKO's BioReference Laboratories' Deal Brings Antibody Testing
by Zacks Equity Research
OPKO Health's (OPK) subsidiary, BioReference Laboratories collaborates with MagnaCare to offer antibody testing to Labor groups in New York metropolitan area.
5 Low Leverage Stocks for Prudent Investors
by Zacks Equity Research
The current market situation seems favorable for corporates to take debt since the COVID-19 pandemic has forced the Federal Reserve to drag down interest rate to a near-zero level.
Here's Why You Should Retain Avanos Medical Stock for Now
by Zacks Equity Research
Avanos Medical (AVNS) continues to benefit from strong performing segments and robust product portfolio. However, stiff competition remains a concern.
Nevro's (NVRO) Senza Omnia SCS System Gets CE Mark Approval
by Zacks Equity Research
Nevro (NVRO) received CE mark approval for the Senza Omnia SCS system, which is likely to boost its international presence.
ResMed Grows on Solid Ventilator Sales Amid Coronavirus Woes
by Zacks Equity Research
ResMed (RMD) global sales increase on ramped-up demand for its critical care support products.
Here's Why You Should Retain Cardinal Health Stock for Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and strategic buyouts.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
ResMed (RMD) Q3 Earnings Top on Higher Ventilator Sales
by Zacks Equity Research
ResMed's (RMD) adjusted gross margin improves on benefits from changes in product mix, and manufacturing and procurement efficiencies.
Will West Pharmaceutical Services Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor West Pharmaceutical Services
Zacks.com featured highlights include: General Mills, Dollar General, West Pharmaceutical Services, Atlas Air Worldwide and CoreLogic
by Zacks Equity Research
Zacks.com featured highlights include: General Mills, Dollar General, West Pharmaceutical Services, Atlas Air Worldwide and CoreLogic
5 Stocks to Add to Your Portfolio on Upgraded Broker Ratings
by Swayta Shah
Amid coronavirus concerns and Q1 earnings in full swing, it is advisable to follow broker ratings to find attractive stocks.
West Pharmaceutical (WST) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
West Pharmaceutical (WST) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
West Pharmaceutical Services (WST) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 23.17% and 5.39%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Why West Pharmaceutical (WST) Might Surprise This Earnings Season
by Zacks Equity Research
West Pharmaceutical (WST) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
West Pharmaceutical Services (WST) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
West Pharmaceutical (WST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can West Pharmaceutical (WST) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
West Pharmaceutical (WST) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Invest in DaVita (DVA) Stock Right Now
by Zacks Equity Research
DaVita (DVA) continues to gain traction from strong international foothold, strategic buyout of dialysis centers and DaVita Kidney Care.
Here's Why You Should Retain Merit Medical (MMSI) Stock Now
by Zacks Equity Research
Merit Medical (MMSI) continues to benefit from growing product pipeline, strong R&D focus and strategic acquisitions.